Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A plant or yeast eukaryotic cell that comprises

a prokaryotic recombinase polypeptide or a nucleic acid that encodes the prokaryotic recombinase, wherein the recombinase is capable of mediating site-specific recombination in the eukaryotic cell between an attB recombination site and an attP recombination site to form an attL and an attR site; and wherein the recombinase is not capable of mediating in the eukaryotic cell recombination between the attL site and the attR site.

Claim 2 (original): The eukaryotic cell of claim 1, wherein the recombinase is selected from the group consisting of a bacteriophage Φ C31 integrase, a coliphage P4 recombinase, a Listeria phage recombinase, a bacteriophage R4 Sre recombinase, a CisA recombinase, and a transposon Tn4451 TnpX recombinase.

Claim 3 (original): The eukaryotic cell of claim 1, wherein the recombinase is a bacteriophage Φ C31 integrase.

Claim 4 (canceled).

Claim 5 (canceled).

Claim 6 (previously presented): The eukaryotic cell of claim 1, wherein the cell comprises a nucleic acid that comprises a coding sequence for the recombinase polypeptide, which coding sequence is operably linked to a promoter that mediates expression of the recombinase-encoding polynucleotide in the eukaryotic cell.

Examining Group 1636

Claim 7 (original): The eukaryotic cell of claim 6, wherein the nucleic acid further comprises a selectable marker.

Claim 8 (original): The eukaryotic cell of claim 6, wherein the promoter is an inducible or a repressible promoter.

Claim 9 (previously presented): The eukaryotic cell of claim 6, wherein the nucleic acid encodes Φ C31 integrase.

Claim 10 (previously presented): The eukaryotic cell of claim 1, wherein the cell is a yeast cell.

Claim 11 (previously presented): The eukaryotic cell of claim 1, wherein the eukaryotic cell is a plant cell.

Claim 12 (previously presented): The eukaryotic cell of claim 11, wherein the eukaryotic cell is present in a plant.

Claims 13 to 35. (canceled).

Claim 36 (previously presented): A plant or yeast eukaryotic cell that comprises: an attP or attB recombination site of bacteriophage ΦC31 integrase integrated in its genome; and

a non-genomic nucleic acid comprising a heterologous nucleic acid or a transgene, and an attP site if the cell has the genomic attB site or an attB site if the cell has the genomic attP site.

Claim 37 (previously presented). The eukaryotic cell of claim 36, wherein the non-genomic nucleic acid comprises the transgene.

Claim 38 (previously presented): The eukaryotic cell of claim 36, wherein the eukaryotic cell further comprises a Φ C31 integrase polypeptide.

Claims 39 to 42 (canceled).

Claim 43 (original): The eukaryotic cell of claim 36, wherein the eukaryotic cell further comprises a nucleic acid that comprises a polynucleotide that encodes a ΦC31 integrase polypeptide.

Claim 44 (original). The eukaryotic cell of claim 43, wherein the nucleic acid further comprises a selectable marker.

Claim 45 (original): The eukaryotic cell of claim 43, wherein the nucleic acid further comprises a promoter which results in expression of the Φ C31 integrase-encoding polynucleotide in the cell.

Claim 46 (original): The eukaryotic cell of claim 45, wherein the promoter is an inducible promoter.

Claim 47 (previously presented): The eukaryotic cell of claim 36, wherein the plant is a dicot or a monocot.

Claim 48 (previously presented): The cell of claim 1, wherein the cell further comprises a heterologous nucleic acid or transgene located between an attR recombination site and an attL recombination site, wherein the heterologous nucleic acid or the transgene is stably integrated into the genome of the cell.

Claim 49 (previously presented): The cell of claim 48, wherein the transgene is located between the *attR* recombination site and the *attL* recombination site and is stably integrated into the genome of the cell.

Claim 50 (previously presented): The cell of claim 2, wherein the cell further comprises a heterologous nucleic acid or transgene located between an attR recombination site and an attL recombination site, wherein said heterologous nucleic acid or transgene is stably integrated into the genome of the cell.

Claim 51 (previously presented): The cell of claim 50, wherein the transgene is located between the attR recombination site and the attL recombination site and is stably integrated into the genome of the cell.

Claim 52 (currently amended): A eucaryotic <u>somatic</u> cell in culture:
comprising an *attP* or *attB* recombination site integrated in its genome;
a non-genomic nucleic acid comprising a transgene or a heterologous nucleic acid
and an *attP* site if the cell has the genomic *attB* site or an *attP* site if the cell has the genomic
attB site.

Claim 53 (currently amended): A <u>non-human</u> eukaryotic cell in culture comprising:

a prokaryotic recombinase polypeptide or a nucleic acid that encodes the prokaryotic recombinase, wherein the recombinase is capable of mediating site-specific recombination in the eukaryotic cell between an attB recombination site and an attP recombination site to form an attL and an attR site, and is not capable of mediating in the eukaryotic cell recombination between the attL site and the attR site; and

a heterologous nucleic acid or transgene located between the attR recombination site and the attL recombination site, wherein said heterologous nucleic acid or transgene is stably integrated into the genome of the cell.

Claim 54 (currently amended): The eukaryotic cell of claim 53, wherein the eukaryotic cell is selected from the group consisting of an animal-cell, a plant cell, a yeast cell, an insect cell and a fungal cell.

Claim 55 (previously presented): The eukaryotic cell of claim 53, wherein the eukaryotic cell is a mammalian cell.

Claim 56 (previously presented). The eukaryotic cell of claim 53, wherein the recombinase is selected from the group consisting of a bacteriophage ΦC31 integrase. a

coliphage P4 recombinase, a Listeria phage recombinase, a bacteriophage R4 Sre recombinase, a CisA recombinase, an XisF recombinase, and a transposon Tn4451 TnpX recombinase.

Claim 57 (previously presented): The eukaryotic cell of claim 56, wherein the recombinase is a bacteriophage Φ C31 integrase.

Claim 58 (currently amended). The eukaryotic cell of claim 53, wherein the cell is an animal a-non-human cell.

Claim 59 (currently amended): The eukaryotic cell of claim 53, wherein the cell is a mouse an embryonic stem cell.

Claim 60 (previously presented): The eukaryotic cell of claim 53, wherein the transgene is located between the *attR* recombination site and the *attL* recombination site and is stably integrated into the genome of the cell.

Claim 61 (previously presented): A method for obtaining site-specific recombination in a eukaryotic cell, the method comprising:

providing a eukaryotic cell that comprises an attB recombination site and an attP recombination site:

contacting the attB and the attP recombination sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination sites, thereby forming an attR and an attL recombination site;

wherein the recombinase polypeptide can mediate site-specific recombination between the attB and attP recombination sites, but cannot mediate recombination between the attR and attL recombination sites.

Claim 62 (previously presented): The method of claim 61, wherein the eukaryotic cell is selected from the group consisting of a yeast cell, a fungal cell, a plant cell, an insect cell and an animal cell.

Claim 63 (previously presented): The method of claim 61, wherein the *attB* recombination site is present in a chromosome of the eukaryotic cell.

Claim 64 (previously presented): The method of claim 63, wherein the attP recombination site is present in a second chromosome of the eukaryotic cell and contacting the attB and attP recombination sites with the recombinase results in translocation of chromosome arms.

Claim 65 (previously presented): The method of claim 61, wherein the *attB* recombination site and the *attP* recombination site are present on a single nucleic acid molecule.

Claim 66 (previously presented): The method of claim 65, wherein the *attB* recombination site and the *attP* recombination site are in a direct orientation.

Claim 67 (previously presented): The method of claim 66, wherein the recombination results in excision of the portion of the nucleic acid molecule that lies between the attB and attP recombination sites.

Claim 68 (previously presented): The method of claim 65, wherein the attB recombination site and the attP recombination site are in an inverted orientation.

Claim 69 (previously presented): The method of claim 68, wherein the recombination results in inversion of the portion of the nucleic acid molecule that lies between the *attB* and *attP* recombination sites.

Claim 70 (previously presented): The method of claim 61, wherein the eukaryotic cell comprises a polynucleotide that encodes the recombinase polypeptide.

Claim 71 (previously presented): The method of claim 61, wherein the attB site is on a first linear DNA fragment and the attP site is on a second linear DNA fragment and contacting the attB and attP sites with the recombinase results in a translocation between the first and second linear DNA fragments.